[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) insider trading report: A company director and officer, who serves as Chief Executive Officer and Chairperson, reported an open-market purchase of 5,000 shares of common stock on 11/14/2025. The shares were bought at a weighted average price of $4.07 per share, with individual trades executed between $4.06 and $4.10.

Following this transaction, the insider beneficially owns 612,822 shares directly. Additional indirect holdings are reported through several family trusts, including 442,765 shares held by the DPH 2008 Trust and smaller positions held by other named family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	11/14/2025		P		5,000	A	$4.07(1)	612,822	D
Common Stock								442,765	I	By the DPH 2008 Trust
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OBIO report in this Form 4?

The filing reports that a director and officer of Orchestra BioMed Holdings, Inc. (OBIO) purchased 5,000 shares of common stock in an open-market transaction on 11/14/2025.

At what price were the 5,000 OBIO shares purchased?

The 5,000 OBIO shares were bought at a weighted average price of $4.07 per share, with individual trades executed between $4.06 and $4.10.

How many OBIO shares does the insider own after this transaction?

After the reported purchase, the insider beneficially owns 612,822 shares directly, plus additional indirect holdings through several family trusts.

What indirect OBIO holdings are reported for the insider?

The insider reports indirect ownership including 442,765 shares held by the DPH 2008 Trust, and smaller amounts held by the Solomon Ascher Hochman 2019 Trust, Hannah Hochman 2019 Trust, Judah Herman Hochman 2019 Trust, and the NSH 2008 Family Trust.

What is the insider’s role at Orchestra BioMed Holdings (OBIO)?

The reporting person is identified as Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc.

Was the OBIO insider purchase executed in multiple trades?

Yes. The filing notes that the reported price is a weighted average and that the shares were purchased in multiple transactions within the $4.06 to $4.10 price range.